TUMOR INFILTRATING LYMPHOCYTE (TIL) therapy is derived from a patient’s own immune cells called lymphocytes that have come to the site of tumor to kill the tumor.
The TIL therapy under investigation in this clinical trial, lifileucel, is expanded and rejuvenated TIL that was extracted from the patient’s own tumor.
ADDITIONAL INFORMATION ABOUT TIL
CLINICAL TRIAL OVERVIEW
IOV-COM-202 is a Phase 2 clinical trial of Iovance TIL therapy (lifileucel, LN-145, LN-144 and LN-145-S1), enrolling patients that have been diagnosed with histologically confirmed unresectable or metastatic melanoma, recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC), recurrent or metastatic non-small cell lung cancer (NSCLC), or relapsed or refractory NSCLC.
For more information on IOV-COM-202 in melanoma, please visit here.